Co-Authors
This is a "connection" page, showing publications co-authored by KELLY K HUNT and THOMAS A BUCHHOLZ.
Connection Strength
9.089
-
Reply to A. Thomsen et al. J Clin Oncol. 2020 10 20; 38(30):3577.
Score: 0.768
-
Multidisciplinary Management of Locoregional Recurrent Breast Cancer. J Clin Oncol. 2020 07 10; 38(20):2321-2328.
Score: 0.753
-
Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy. J Natl Cancer Inst Monogr. 2015 May; 2015(51):11-4.
Score: 0.530
-
Breast conservation therapy in the 21st century. Breast J. 2011 Sep-Oct; 17(5):445-7.
Score: 0.411
-
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003 Dec 01; 98(11):2522-3; author reply 2523-4.
Score: 0.240
-
Radiation therapy as an adjuvant treatment after sentinel lymph node surgery for breast cancer. Surg Clin North Am. 2003 Aug; 83(4):911-30, x.
Score: 0.235
-
1st annual oncology update: advances and controversies. Steamboat Springs, Colorado, USA, 13-17 February 2001. Expert Rev Anticancer Ther. 2001 Jun; 1(1):6-8.
Score: 0.202
-
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001 Apr 15; 19(8):2240-6.
Score: 0.200
-
Postmastectomy Radiation Treatment Rates as a Quality Measure: An Opportunity for Compliance Through Collaboration. Ann Surg Oncol. 2016 08; 23(8):2377-9.
Score: 0.142
-
Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
Score: 0.123
-
Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013 Feb; 257(2):173-9.
Score: 0.113
-
Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy. Ann Surg Oncol. 2013 May; 20(5):1514-21.
Score: 0.112
-
Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012 Sep; 256(3):428-36.
Score: 0.110
-
Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer. 2012 Oct 15; 118(20):4936-43.
Score: 0.107
-
Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011 Dec 10; 29(35):4654-61.
Score: 0.104
-
Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol. 2011 Dec 01; 29(34):4479-81.
Score: 0.104
-
A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: 3-year follow-up. Plast Reconstr Surg. 2011 Jun; 127(6):2154-2166.
Score: 0.101
-
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011 May 20; 29(15):1956-62.
Score: 0.100
-
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9.
Score: 0.099
-
Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer. 2011 Apr 15; 117(8):1595-601.
Score: 0.097
-
Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010 Sep 01; 116(17):4000-6.
Score: 0.096
-
Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010 Aug 01; 77(5):1296-302.
Score: 0.094
-
Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. J Am Coll Surg. 2009 Oct; 209(4):425-433.e2.
Score: 0.089
-
A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects. Plast Reconstr Surg. 2008 Dec; 122(6):1631-1647.
Score: 0.085
-
Staging of breast cancer in the neoadjuvant setting. Cancer Res. 2008 Aug 15; 68(16):6477-81.
Score: 0.083
-
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):474-84.
Score: 0.081
-
Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1022-7.
Score: 0.080
-
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008 Jan 10; 26(2):246-52.
Score: 0.079
-
Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer. 2007 Dec 01; 110(11):2420-7.
Score: 0.079
-
Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007 Oct; 194(4):527-31.
Score: 0.078
-
Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007 Aug 15; 110(4):723-30.
Score: 0.078
-
Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1004-9.
Score: 0.076
-
Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):490-6.
Score: 0.075
-
Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol. 2006 Nov 01; 24(31):4971-5.
Score: 0.074
-
Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg. 2006 Oct; 192(4):552-5.
Score: 0.073
-
Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys. 2006 Oct 01; 66(2):352-7.
Score: 0.072
-
Immediate breast reconstruction can impact postmastectomy irradiation. Am J Clin Oncol. 2005 Oct; 28(5):485-94.
Score: 0.068
-
Now and later? The sticky question of lymph node management in patients receiving preoperative chemotherapy. Ann Surg Oncol. 2005 Sep; 12(9):683-5.
Score: 0.067
-
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):351-7.
Score: 0.067
-
Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Apr 15; 103(8):1581-6.
Score: 0.066
-
Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer. 2005 Apr 01; 103(7):1323-9.
Score: 0.066
-
Paget's disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol. 2005 May; 12(5):391-7.
Score: 0.066
-
Breast conservation after neoadjuvant chemotherapy. Cancer. 2005 Feb 15; 103(4):689-95.
Score: 0.065
-
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004 Dec 01; 22(23):4691-9.
Score: 0.064
-
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42.
Score: 0.063
-
Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1074-9.
Score: 0.063
-
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004 Jun 15; 22(12):2303-12.
Score: 0.062
-
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):138-45.
Score: 0.062
-
Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):336-44.
Score: 0.059
-
Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer. 2003 Sep 15; 98(6):1150-60.
Score: 0.059
-
Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):128-35.
Score: 0.059
-
Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol. 2003 Sep 01; 21(17):3244-8.
Score: 0.059
-
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003 Feb 15; 97(4):926-33.
Score: 0.057
-
Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002 Nov 15; 95(10):2059-67.
Score: 0.056
-
Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1225-33.
Score: 0.055
-
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2002 Jul 15; 53(4):880-8.
Score: 0.055
-
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol. 2002 Jul; 9(6):543-9.
Score: 0.054
-
A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol. 2002 Apr; 9(3):228-34.
Score: 0.054
-
Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol. 2002 Apr; 9(3):256-65.
Score: 0.054
-
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002 Jan 01; 20(1):17-23.
Score: 0.053
-
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001 Dec; 182(6):601-8.
Score: 0.052
-
Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):671-8.
Score: 0.052
-
Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. Int J Radiat Oncol Biol Phys. 2021 10 01; 111(2):360-370.
Score: 0.050
-
Local-regional control in breast cancer patients with a possible genetic predisposition. Int J Radiat Oncol Biol Phys. 2000 Nov 01; 48(4):951-7.
Score: 0.049
-
Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol. 2000 Oct; 7(9):656-64.
Score: 0.048
-
Quantitative 3-Dimensional Photographic Assessment of Breast Cosmesis After Whole Breast Irradiation for Early Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. Adv Radiat Oncol. 2020 Sep-Oct; 5(5):824-833.
Score: 0.047
-
Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):174-182.
Score: 0.044
-
Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am. 1999 May-Jun; 5(3):159-64.
Score: 0.044
-
Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer. Ann Surg Oncol. 1999 Jan-Feb; 6(1):102-8.
Score: 0.043
-
Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. J Clin Oncol. 2018 Oct 31; JCO1800317.
Score: 0.042
-
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.
Score: 0.037
-
Quantitative Assessment of Breast Cosmetic Outcome After Whole-Breast Irradiation. Int J Radiat Oncol Biol Phys. 2017 04 01; 97(5):894-902.
Score: 0.037
-
Cost and Complications of Local Therapies for Early-Stage Breast Cancer. J Natl Cancer Inst. 2017 01; 109(1).
Score: 0.037
-
Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):637-44.
Score: 0.036
-
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr; 2(4):508-16.
Score: 0.035
-
Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes. Ann Surg Oncol. 2016 08; 23(8):2385-90.
Score: 0.035
-
Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):493-502.
Score: 0.034
-
Sonography and Sonographically Guided Needle Biopsy of Internal Mammary Nodes in Staging of Patients With Breast Cancer. AJR Am J Roentgenol. 2015 Oct; 205(4):905-11.
Score: 0.034
-
Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015 Oct; 1(7):931-41.
Score: 0.034
-
Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10.
Score: 0.033
-
Utilization and Outcomes of Breast Brachytherapy in Younger Women. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):91-101.
Score: 0.033
-
Surgeon influence on use of needle biopsy in patients with breast cancer: a national medicare study. J Clin Oncol. 2014 Jul 20; 32(21):2206-16.
Score: 0.031
-
Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: impact of patient stratification on breast preservation. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):274-84.
Score: 0.030
-
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 09; 310(14):1455-61.
Score: 0.030
-
Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: implications for targeting the undissected axilla. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):116-122.
Score: 0.029
-
Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol. 2013 Oct; 20(11):3430-7.
Score: 0.029
-
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013 Aug; 24(8):1999-2004.
Score: 0.029
-
Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer. 2012 Dec 15; 118(24):6287-96.
Score: 0.027
-
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012 May 23; 14(3):R82.
Score: 0.027
-
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012 May 23; 14(3):R83.
Score: 0.027
-
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12.
Score: 0.026
-
Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):782-7.
Score: 0.026
-
Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. 2012 Mar 15; 118(6):1507-14.
Score: 0.026
-
Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7.
Score: 0.026
-
Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat. 2011 Jul; 128(2):421-7.
Score: 0.025
-
Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908.
Score: 0.023
-
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med. 2009 May 26; 6(5):e1000068.
Score: 0.022
-
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7909-16.
Score: 0.021
-
Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy. Plast Reconstr Surg. 2007 Dec; 120(7):1755-1768.
Score: 0.020
-
Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged
View in: PubMed
Score: 0.020
Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol. 2007 Apr; 14(4):1458-71.
Score: 0.019
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 01; 13(1):228-33.
Score: 0.019
Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. J Am Coll Surg. 2006 Jul; 203(1):64-72.
Score: 0.018
Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50.
Score: 0.017
Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. Am J Surg Pathol. 2005 Nov; 29(11):1456-63.
Score: 0.017
Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer. 2005 Aug 01; 104(3):479-90.
Score: 0.017
Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer. 2005 Jul 01; 104(1):20-9.
Score: 0.017
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85.
Score: 0.016
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol. 2004 Sep; 11(9):854-60.
Score: 0.016
Delayed-immediate breast reconstruction. Plast Reconstr Surg. 2004 May; 113(6):1617-28.
Score: 0.015
Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004 Mar 01; 100(5):942-9.
Score: 0.015
Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer. 2004 Feb 01; 100(3):490-8.
Score: 0.015
Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction. Am J Surg. 2004 Feb; 187(2):164-9.
Score: 0.015
Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol. 2003 Jul; 10(6):628-34.
Score: 0.015
Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol. 2002 Nov; 9(9):912-9.
Score: 0.014
Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg. 2002 Jan; 194(1):54-64.
Score: 0.013
Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. Cancer. 2001 Sep 01; 92(5):1092-100.
Score: 0.013
Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001 Jun; 8(5):425-31.
Score: 0.013
Presentation, management and outcome of axillary recurrence from breast cancer. Am J Surg. 2000 Oct; 180(4):252-6.
Score: 0.012
Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol. 2000 Jul; 7(6):435-40.
Score: 0.012
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999 Feb; 17(2):460-9.
Score: 0.011
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998 Dec; 176(6):502-9.
Score: 0.011
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am. 1998 Jul-Aug; 4(4):230-6.
Score: 0.010